Treatment of screen detected ductal carcinoma in situ: a silver lining within a grey cloud?
作者信息
Fentiman I S
出版信息
Br J Cancer. 1990 Jun;61(6):795-6. doi: 10.1038/bjc.1990.179.
Abstract
摘要
相似文献
1
Treatment of screen detected ductal carcinoma in situ: a silver lining within a grey cloud?筛查发现的导管原位癌的治疗：乌云中的一线希望？
Br J Cancer. 1990 Jun;61(6):795-6. doi: 10.1038/bjc.1990.179.
2
3
Is radiotherapy as curative as mastectomy for patients with ductal carcinoma in situ?对于导管原位癌患者，放射治疗与乳房切除术的疗效一样吗？
Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):1091-2; discussion 1103. doi: 10.1016/0360-3016(90)90039-m.
4
Breast conservation therapy for ductal carcinoma in situ.导管原位癌的保乳治疗
Int J Radiat Oncol Biol Phys. 1993 Jun 15;26(3):547-8; discussion 549. doi: 10.1016/0360-3016(93)90975-2.
5
The problem of ductal carcinoma in situ of the breast.乳腺导管原位癌问题
Ann Chir Gynaecol. 1992;81(4):334-6.
6
Radiotherapy for ductal carcinoma in situ detected by screening.筛查发现的导管原位癌的放射治疗
BMJ. 1990 Jul 28;301(6745):224-5. doi: 10.1136/bmj.301.6745.224.
7
Evaluation of treatment options for ductal carcinoma in situ of the breast.乳腺导管原位癌治疗方案的评估
Arch Surg. 1991 Dec;126(12):1541-2. doi: 10.1001/archsurg.1991.01410360119019.
8
Current management of noninvasive (in situ) breast cancer.非侵袭性（原位）乳腺癌的当前管理
Adv Surg. 2000;34:17-41.
9
[Minimal carcinoma of the breast].[乳腺微小癌]
Ann Ital Chir. 1991 Sep-Oct;62(5):427-31.
10
Surgical implications of population screening for mammary carcinoma.人群乳腺癌筛查的手术意义
Eur J Surg Oncol. 1990 Feb;16(1):15-7.
引用本文的文献
1
Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast.pS2蛋白在乳腺导管原位癌及良性病变中的免疫组化定位
Br J Cancer. 1993 Apr;67(4):749-53. doi: 10.1038/bjc.1993.136.
2
Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein.乳腺导管原位癌中雌激素受体的表达：与DNA流式细胞术分析及c-erbB-2癌蛋白表达的关系。
Br J Cancer. 1993 Jul;68(1):156-61. doi: 10.1038/bjc.1993.305.
3
Ductal carcinoma in situ.导管原位癌
BMJ. 1992 May 16;304(6837):1261-2. doi: 10.1136/bmj.304.6837.1261.
本文引用的文献
1
Ten- to fourteen-year effect of screening on breast cancer mortality.筛查对乳腺癌死亡率的10至14年影响。
J Natl Cancer Inst. 1982 Aug;69(2):349-55.
2
Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.神经蛋白在乳腺癌中的过表达。与粉刺型导管原位癌相关及在II期乳腺癌中的预后价值有限。
N Engl J Med. 1988 Nov 10;319(19):1239-45. doi: 10.1056/NEJM198811103191902.
3
Tamoxifen and benign breast problems.
Lancet. 1987 Nov 7;2(8567):1070-2. doi: 10.1016/s0140-6736(87)91491-7.
4
Tamoxifen and contralateral breast cancer.
Lancet. 1985 Aug 3;2(8449):282. doi: 10.1016/s0140-6736(85)90338-1.
5
Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare.乳腺钼靶筛查后乳腺癌死亡率的降低。瑞典国家卫生和福利委员会乳腺癌筛查工作组的随机试验。
Lancet. 1985 Apr 13;1(8433):829-32. doi: 10.1016/s0140-6736(85)92204-4.
6
Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer.乳腺癌术后辅助放疗随机试验综述
Cancer Treat Rep. 1987 Jan;71(1):15-29.
7
In-situ breast cancer: the EORTC consensus meeting.原位乳腺癌：欧洲癌症研究与治疗组织共识会议
Lancet. 1989 Jul 1;2(8653):25-7. doi: 10.1016/s0140-6736(89)90263-8.
8
Comparative features of ductal carcinoma in situ and infiltrating ductal carcinoma of the breast on fine-needle aspiration biopsy.乳腺导管原位癌和浸润性导管癌在细针穿刺活检中的比较特征
Am J Clin Pathol. 1989 Dec;92(6):736-40. doi: 10.1093/ajcp/92.6.736.
9
Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence.乳腺钼靶检查发现的导管原位癌。乳房局部切除术后局部复发的频率以及核分级对局部复发的预后影响。
Cancer. 1989 Feb 15;63(4):618-24. doi: 10.1002/1097-0142(19890215)63:4<618::aid-cncr2820630403>3.0.co;2-j.
10
Edinburgh trial of screening for breast cancer: mortality at seven years.爱丁堡乳腺癌筛查试验：七年死亡率
Lancet. 1990 Feb 3;335(8684):241-6. doi: 10.1016/0140-6736(90)90066-e.
Zotero 插件